COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Effect of a Natural Polyphenolic Extract From Pomegrnate (POMX) on the Development of Atherosclerosis in Diabetic Patients (POMX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00470808
Recruitment Status : Unknown
Verified April 2007 by HaEmek Medical Center, Israel.
Recruitment status was:  Not yet recruiting
First Posted : May 8, 2007
Last Update Posted : May 8, 2007
Information provided by:
HaEmek Medical Center, Israel

Brief Summary:
Diabetes is a highly atherogenic disease. Pomegranate juice has impressive antioxidant properties. It has been proven to decrease oxidant stress and to cause the regression of atherosclerotic plaques in hypercholestrolemic and diabetic patients.Furthermore it has been proven to potentiate the biologic activity of the enzyme paraoxonase 1 which is very important in preventing atherosclerosis. The study will try to prove that a polyphenolic extract from pomegranate (POMx) has the same desired effects.

Condition or disease Intervention/treatment Phase
Atherosclerosis Drug: POMx Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : May 2007
Estimated Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Atherosclerosis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males
  • HBA1C>7%
  • Drug therapy given for DM

Exclusion Criteria:

  • Age<18
  • Inclusion in another study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00470808

Layout table for location contacts
Contact: Wasseem Rock, MD 0547866896

Layout table for location information
Ha'Emek Medical Center
Afula, Israel, 18101
Contact: Wasseem Rock, MD    0547-866806      
Principal Investigator: Wasseem Rock, MD         
Sponsors and Collaborators
HaEmek Medical Center, Israel
Layout table for investigator information
Principal Investigator: Wasseem Rock, MD Ha'Emek Medical Center
Layout table for additonal information Identifier: NCT00470808    
Other Study ID Numbers: 0051-07-EMC
First Posted: May 8, 2007    Key Record Dates
Last Update Posted: May 8, 2007
Last Verified: April 2007
Keywords provided by HaEmek Medical Center, Israel:
Enrollment in another study
HBA1C greater than 7
Drug therapy for DM
Additional relevant MeSH terms:
Layout table for MeSH terms
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases